Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare RoyaltyBusiness Wire • 12/20/22
Atara Biotherapeutics' Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLDBusiness Wire • 12/19/22
Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual MeetingBusiness Wire • 12/12/22
Atara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx ConferenceBusiness Wire • 11/23/22
Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational ProgressBusiness Wire • 11/08/22
Atara Biotherapeutics to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022Business Wire • 11/01/22
Atara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022Business Wire • 10/26/22
CHMP Recommends Approval of Atara Biotherapeutics' Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative DiseaseBusiness Wire • 10/14/22
Atara Biotherapeutics to Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel (Tab-cel®) Commercialization Agreement with Pierre FabreBusiness Wire • 09/28/22
These Were the Five Best and Worst Performing Small-Cap Stocks in August 202224/7 Wall Street • 09/06/22
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Citigroup 17th Annual Biopharma ConferenceBusiness Wire • 08/31/22
Does Atara Biotherapeutics (ATRA) Have the Potential to Rally 204% as Wall Street Analysts Expect?Zacks Investment Research • 08/15/22
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/08/22
Atara Biotherapeutics (ATRA) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/08/22
Atara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy UpdateBusiness Wire • 08/08/22
ATARA ALERT: Bragar Eagel & Squire, P.C. is Investigating Atara Biotherapeutics, Inc. on Behalf of Atara Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 08/06/22